PMID- 12943485
OWN - NLM
STAT- MEDLINE
DCOM- 20031014
LR  - 20190916
IS  - 1465-6566 (Print)
IS  - 1465-6566 (Linking)
VI  - 4
IP  - 9
DP  - 2003 Sep
TI  - Review of bemiparin sodium--a new second-generation low molecular weight heparin 
      and its applications in venous thromboembolism.
PG  - 1551-61
AB  - Bemiparin sodium (Hibor, Ivor, Zivor, Badyket, Laboratorios Farmaceuticos Rovi 
      SA) is a new second-generation low molecular weight heparin (LMWH). Bemiparin has 
      the lowest mean molecular weight (3600 Da), the longest half-life (5.3 h) and the 
      largest antifactor Xa:antifactor IIa ratio (8:1) of all LMWHs. Bemiparin promotes 
      a greater release of tissue factor pathway inhibitor than unfractionated heparin 
      (UFH) or dalteparin. These properties could result in a more favourable 
      efficacy:safety ratio than the currently marketed LMWHs. Bemiparin 2500 IU/day 
      was as effective as UFH for preventing venous thromboembolism (VTE) in moderate 
      risk abdominal surgery. Bemiparin 3500 IU/day significantly reduced VTE compared 
      to UFH in high-risk hip replacement surgery. Bemiparin 3500 IU/day started 
      postoperatively was as effective as enoxaparin 4000 IU/day started preoperatively 
      in total knee arthroplasty, with a trend towards a lower rate of proximal deep 
      vein thrombosis (DVT), pulmonary embolism and symptomatic VTE. In patients with 
      acute DVT, bemiparin was more effective than UFH in thrombus mass reduction and 
      at least as effective as UFH for the prevention of clinical recurrence. Bemiparin 
      was as effective as UFH for clot prevention during haemodialysis. The use of 
      bemiparin was associated with a lower incidence of major and minor bleeding as 
      compared to UFH in abdominal surgery. When compared with enoxaparin in 
      orthopaedic surgery, a lower rate of complications at injection site was 
      observed.
FAU - Planes, Andre
AU  - Planes A
AD  - Orthopedic Department, Clinique Radio-Chirurgicale du Mail, La Rochelle, France. 
      aplanes107@aol.com
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - PUE0TO3XDR (bemiparin)
SB  - IM
MH  - Fibrinolytic Agents/adverse effects/pharmacology/*therapeutic use
MH  - Heparin, Low-Molecular-Weight/adverse effects/pharmacology/*therapeutic use
MH  - Humans
MH  - Injections, Subcutaneous
MH  - Postoperative Complications/prevention & control
MH  - Product Surveillance, Postmarketing
MH  - Renal Dialysis/adverse effects
MH  - Surgical Procedures, Operative/adverse effects
MH  - Thromboembolism/etiology/*prevention & control
MH  - Venous Thrombosis/etiology/*prevention & control
RF  - 56
EDAT- 2003/08/29 05:00
MHDA- 2003/10/15 05:00
CRDT- 2003/08/29 05:00
PHST- 2003/08/29 05:00 [pubmed]
PHST- 2003/10/15 05:00 [medline]
PHST- 2003/08/29 05:00 [entrez]
AID - 10.1517/14656566.4.9.1551 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2003 Sep;4(9):1551-61. doi: 10.1517/14656566.4.9.1551.